Regina E. Groves

Regina E. Groves is a declared insider at 3 companies (board member); the most frequent names are AtriCure, Inc., REVA Medical, Inc. and Fulgent Genetics, Inc. The record holds 31 filings, for trades running from 30 March 2016 to 11 September 2026.

Both buying and selling appear: 10 purchases worth €73k, against 5 sales worth €996k. The net balance comes to €922k on the selling side. Unlike grants, an open-market purchase is paid for by the insider, at the market price. Outside the open market, there are 16 share grants. Since January 2026: no purchases and 1 sale on the market.

A typical purchase (the median) is worth €4,608. Of 10 purchases, 7 formed part of a group of insiders buying within 30 days of each other. Purchases made close together by different insiders form what is called a cluster. Looking at 3 purchases old enough to measure, the stock rose over the following 90 days in 67% of cases; the median change was +17.5%. They describe history only and say nothing certain about the share price ahead.

The record was last updated on 14 September 2026 with an open-market sale (€248k) in AtriCure, Inc. The latest purchase dates back some time: it was published 1,821 days ago, on 29 October 2021. Between a trade and the moment it shows up on SEC (Form 4), the median delay is 2 days. US insiders must file a Form 4 within two business days of a trade. These figures are compiled from regulatory filings published by SEC (Form 4). They describe what insiders did and are not a recommendation.